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and Bruno Pradines4,5,6Abstract
Background: Malaria still has significant impacts on the world; particularly in Africa, South America and Asia where
spread over several millions of people and is one of the major causes of death. When chloroquine diphosphate (CQDP)
lost its efficiency as a first-line anti-malarial drug, this was a major setback in the effective control of malaria. Currently,
malaria is treated with a combination of two or more drugs with different modes of action to provide an adequate cure
rate and delay the development of resistance. Clearly, a new effective and non-toxic anti-malarial drug is urgently needed.
Methods: All metal-chloroquine (CQ) and metal-CQDP complexes were synthesized under N2 using Schlenk techniques.
Their interactions with haematin and the inhibition of β-haematin formation were examined, in both aqueous medium
and near water/n-octanol interfaces at pH 5. The anti-malarial activities of these metal- CQ and metal-CQDP complexes
were evaluated in vitro against two strains, the CQ-susceptible strain (CQS) 3D7 and the CQ-resistant strain (CQR) W2.
Results: The previously synthesized Au(CQ)(Cl) (1), Au(CQ)(TaTg) (2), Pt(CQDP)2Cl2 (3), Pt(CQDP)2I2 (4), Pd(CQ)2Cl2 (5) and
the new one Pd(CQDP)2I2 (6) showed better anti-malarial activity than CQ, against the CQS strain; moreover, complexes 2,
3 and 4 were very active against CQR strain. These complexes (1–6) interacted with haem and inhibited β-haematin
formation both in aqueous medium and near water/n-octanol interfaces at pH 5 to a greater extent than chloroquine
diphosphate (CQDP) and other known metal-based anti-malarial agents.
Conclusions: The high anti-malarial activity displayed for these metal-CQ and metal-CQDP complexes (1–6) could be
attributable to their effective interaction with haem and the inhibition of β-haematin formation in both aqueous medium
and near water/n-octanol interfaces at pH 5.
Keywords: Malaria, Plasmodium falciparum, Anti-malarial, in vitro, Resistance, Gold, Platinum, Chloroquine, β-hematinBackground
Approximately 3.3 billion people, one half of the world’s
population, live in at-risk regions for malaria infection. In
2013, an estimated 207 million episodes of malaria oc-
curred, and approximately 627,000 people died [1]. Of the
five typically recognized Plasmodium species causing this
disease in humans, Plasmodium falciparum is responsible
for about 95% of malaria worldwide and has a mortality
rate of 1–3%, and Plasmodium vivax for most morbidity,* Correspondence: maribelnava@gmail.com
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unless otherwise stated.additionally representing a reservoir of latent infection
that hampers current control and future elimination
efforts [2,3].
When chloroquine resistant (CQR) malaria parasites
started to emerge in Asia and South America and spread
from Asia to Africa, and lost its efficiency as a first line
anti-malarial drug, this was a major setback to the effect-
ive control of malaria. Currently, malaria is treated with a
combination of two or more drugs with different modes of
action to provide an adequate cure rate and delay develop-
ment of resistance.
A strategy for the development of alternative therapies
against malaria has been based on the modification of
compounds with known or potential activity through thel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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structure, this modification is important within biological
systems due to the binding capability and reactivity of the
transition metals, which are determined by the d orbitals
[4]. A variety of metal complexes has been developed as
possible anti-malarial agents [5-8], progressed from simple
“synthesis/activity” to complex insights into their mecha-
nisms of action, these concepts open new perspectives in
drug design, for example Sanchez-Delgado and Navarro
groups have proposed the modification of CQ through the
incorporation of a transition metal into the molecular
structure. Indeed, several metal centres (Rh, Ru, Ir and
Au) have been used finding that the most significant re-
sults have been obtained for the centers of ruthenium
[9,10] and gold [11,12].
Encouraged by these interesting biological results the
studies of the mechanism of action of these metal-
chloroquine complexes ([RuCl2(CQ)]2 and [Au(CQ)
(PPh3)]PF6) were evaluated on two important targets,
Fe(III)PPIX and DNA [13,14], finding that the main
mechanism of anti-malarial action of these [RuCl2(CQ)]2
and [Au(CQ)(PPh3)]PF6 complexes against resistant
strains of P. falciparum was the inhibition of β-haematin
formation. Both the enhanced activity and the ability of
these compounds to lower CQ resistance are related to
the high lipophilicity of the metal complexes and the im-
portant structural modification of the CQ structure im-
posed by the presence of the metal-containing fragment.
Taking into account the importance of the interactions
of these metal compounds with the specific targets Fe(III)
PPIX and the relevance of the inhibition of β-haematinin
order to increase anti-plasmodial activity and avoid para-
site resistance, the interaction of six metal-CQ (metal: Au,
Pt and Pd) complexes with ferriprotoporphyrin, their abil-
ity to inhibit the haem aggregation at water/lipid interfaces
and their anti-malarial activity against 3D7 and W2 strains
(CQ-susceptible strain and CQ-resistant strain, respect-
ively) were assessed in the present work. Worthy of men-
tioning, that the cytotoxic activity against the six tumor
cell lines, of five of these metal-CQ complexes have already
been reported [15,16] that significant activity was attrib-
uted mainly to their interaction with the DNA. Addition-
ally, the synthesis and characterization of the new Pd
(CQDP)2I2 complex were reported here.
Methods
All manipulations were carried out under N2 using com-
mon Schlenk techniques. Solvents were purified by stand-
ard procedures immediately prior to use. Chloroquine
diphosphate (CQDP), chloride haemin, buffers and sol-
vents were purchased from Sigma-Aldrich. All other com-
mercial reagents were used without further purification.
Metal–CQ and Metal–CQDP (1–5) complexes were pre-
pared according to the literature [15-17]. The NMRspectra were obtained in a DMSO solution in a Bruker
AVANCE 500 spectrometer. 1H NMR shifts were re-
corded relative to residual proton resonances in the deu-
terated solvent. IR spectra were obtained with a Nicolet
Magna IR 560 spectrometer. ESI mass spectra were ob-
tained by using a Thermo FINNIGAN LXQ with methanol
as the solvent. UV–vis spectra and all the spectrophotomet-
ric studies experiments were performed on an Agilent 8453
diode-array spectrophotometer.
Synthesis and characterization of complex Pd(CQDP)2I2 (6)
A solution of K2[PdCl4] (65.3 mg, 0.2 mmol) in water
(20 mL) was stirred until complete dissolution was
achieved, an excess (20-fold) of KI was added. Then, CQDP
dissolved in water (206.4 mg, 0.4 mmol) was added. The
stirring was continued for 1 h at room temperature, and a
brown precipitate was obtained. This was collected by fil-
tration, washed with water, and dried under vacuum. Spec-
troscopic and analytical characterization of this complex
was described in Additional file 1.
In vitro anti-malarial activity
The two strains, 3D7, the CQ-susceptible strain (isolated
in West Africa; obtained from MR4, VA, USA), and W2
(isolated in Indochina; obtained from MR4, VA, USA), the
CQ-resistant strain, were maintained in culture in RPMI
1640 (Invitrogen, Paisley, UK), supplemented with 10%
human serum (Abcys S.A. Paris, France) and buffered with
25 mM HEPES and 25 mM NaHCO3. Parasites were
grown in A-positive human blood (Etablissement Français
du Sang, Marseille, France) under controlled atmospheric
conditions that consisted of 10% O2, 5% CO2 and 85% N2
at 37°C with a humidity of 95%.
The two strains were synchronized twice with sorbitol
before use [18], and clonality was verified every 15 days
through PCR genotyping of the polymorphic genetic
markers msp1 and msp2 and microsatellite loci [19,20];
additionally, clonality was verified each year by an inde-
pendent laboratory from the Worldwide Anti-malarial
Resistance Network (WWARN).
Chloroquine diphosphate (CQDP) was purchased from
Sigma (Saint Louis, MO). CQDP was resuspended in
water in concentrations ranging between 5 to 3200 nM.
The synthetic compounds were resuspended in DMSO
and then diluted in RPMI-DMSO (99v/1v) to obtain
final concentrations ranging from 1 nM to 100 μM.
For in vitro isotopic microtests, 25 μL/well of anti-
malarial drug and 200 μL/well of the parasitized red blood
cell suspension (final parasitaemia, 0.5%; final haematocrit,
1.5%) were distributed into 96 well plates. Parasite growth
was assessed by adding 1 μCi of tritiated hypoxanthine
with a specific activity of 14.1 Ci/mmol (Perkin-Elmer,
Courtaboeuf, France) to each well at time zero. The plates
were then incubated for 48 h in controlled atmospheric
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frozen and thawed to lyse erythrocytes. The contents of
each well were collected on standard filter microplates
(Unifilter GF/B; Perkin-Elmer) and washed using a cell
harvester (Filter-Mate Cell Harvester; Perkin-Elmer). Filter
microplates were dried, and 25 μL of scintillation cocktail
(Microscint O; Perkin-Elmer) was placed in each well.
Radioactivity incorporated by the parasites was measured
with a scintillation counter (Top Count; Perkin-Elmer).
The IC50, the drug concentration able to inhibit 50%
of parasite growth, was assessed by identifying the drug
concentration corresponding to 50% of the uptake of
tritiated hypoxanthine by the parasite in the drug-free
control wells. The IC50 value was determined by non-
linear regression analysis of log-based dose–response
curves (Riasmart™, Packard, Meriden, USA). IC50 are
expressed as geometric means of 6 experiments.
Interaction with haematin
The association constant of compounds metal-CQ with
ferriprotoporphyrin IX (Fe(III)PPIX) was measured as de-
scribed previously [21]. Briefly, a stock solution of haemin
was prepared by dissolving 3.5 mg of haemin in 15 mL
DMSO. Aqueous-DMSO (40% v/v) solutions of Fe(III)
PPIX (pH 7.5) were prepared daily by mixing 140 μL hae-
min stock solution with 4 mL DMSO and 1 mL 0.2 M
(Tris; Tris(hydroxymethyl)aminomethane) Tris buffer
(pH 7.5) and completed to 10 mL with doubly distilled de-
ionized water. The concentration of Fe(III)PPIX in this so-
lutions was 4 μM and absorbance readings were recorded
at 402 nm. The reference cell containing 40% v/v DMSO,
0.020 M Tris pH 7.5 was also titrated with each complex
in order to blank out the absorbance of the drug. The data
were fitted to the equation A = (A0 + A∞K[C])/(1 + K[C])
for a 1:1 complexation model using nonlinear least
squares fitting, strictly following the procedure of Egan
et al. [22], with omission of the first few data points at very
low drug-to-haematin ratio, where the fit is poor. A0 is the
absorbance of haemin before addition of complex, A∞ is
the absorbance for the drug–haemin adduct at saturation,
A is the absorbance at each point of the titration, and K is
the conditional association constant.
Inhibition of β-haematin formation
The transformation of haemin to β-haematin in acidic
acetate solutions was studied using infrared spectroscopy
using the method developed by Egan et al. [22]. The
IC50 of β-Haematin formation in buffer assay was per-
formed according to Dominguez [23]. Briefly, a solution
of haemin (50 μL, 4 mM), dissolved in DMSO, was dis-
tributed in 96-well micro plates. The complex was dis-
solved in DMSO and added in triplicate in test wells
(50 μL) to final concentrations of 0–20 mM/well. Con-
trols contained water and DMSO. Haemozoin formationwas initiated by the addition of acetate buffer (100 μL
0.2 M, pH 4.4). Plates were incubated at 37°C for 48 h to
allow completion of the reaction and centrifuged at
4,000 RPM× 15 min. After discarding the supernatant,
the pellet was washed twice with DMSO (200 μL) and fi-
nally dissolved in NaOH (200 μL, 0.2 N). The solutions
were further diluted 1:2 with NaOH (0.1 N) and absorb-
ance recorded at 405 nm. The results were expressed as
a percentage of inhibition of haemozoin formation.
β-Haematin formation at a water/octanol interface was
followed according to a method proposed by Egan and
coworkers [24] and modified by Martínez et al. [25].
Haemin was dissolved in 0.1 M NaOH solution to gener-
ate haematin and acetone was added until the acetone:
water ratio was 4: 6; the final solution contained 15 mg
haematin/mL. A sample of this solution (200 μL) was
carefully introduced close to the interface between n-
octanol (2 mL) and aqueous acetate buffer (5 mL, 8 M;
pH 4.9) in a cylindrical vial with an internal diameter of
2.5 cm. The mixture was incubated at 37°C for 2 h and
at the end of the incubation the product (β-haematin)
was isolated by centrifugation. The pellet was collected
and washed twice with DMSO (2 mL), centrifuged again
for 20 min, washed with 2 mL of ethanol and finally dis-
solved in 25 mL of 0.1 M NaOH for spectrophotometric
quantification. For the haem aggregation inhibition ac-
tivity measurements the appropriate amount of the drug
(23 mM in DMSO) was dissolved; after stirring for
30 min to equilibrate the drug between the two phases,
the haematin solution was added close to the interface
and the procedure was followed as described above. All
experiments were performed in triplicate.
Results and discussion
Synthesis and characterization of complex Pd(CQDP)2(I)2 (6)
The palladium-chloroquine diphosphate complex was
synthesized at room temperature in water. An excess of
KI was added to the solution of K2[PdCl4] in order to
displace all chloride ligands; subsequently, CQDP was
added in a ratio 2:1 with respect to palladium salt, dis-
placed two iodide ligands leads to the new complex(6),
which was isolated in good yields as air stable brown solid.
Elemental analyses of this complex are in agreement with
the molecular formula proposed. The IR spectra of the
complexes displayed peaks clearly associated with the pres-
ence of the coordinated CQDP. The ESI-MS spectrum of
complex displayed a peak of high intensity corresponding
to a molecular ion (M - 4H3PO4) at m/z 1000.03. The
molar conductivity values obtained for the complex is in
the range for 1:4 electrolytes dissolved in DMF [26], corre-
sponding to four phosphates (H2PO4
−) of CQDP in the
complex. All NMR signals could be unequivocally assigned
on the basis of 1D and 2D, Correlation spectroscopy
(COSY), Heteronuclear Multiple Quantum Correlation
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(HMBC) experiments for both complexes (for complete
NMR data see Annex 1; atom numbering for CQDP in
Figure 1). The 1H and 31C chemical shift variation of each
signal with respect to those of the free ligand (Δδ) was used
as a parameter to deduce the mode of bonding of CQDP
to the metal. It has been previously shown [9-12,27] that
the largest variations are always observed for the protons
and carbons located in the vicinity of the N-atom attached
to the metal. The largest shift with respect to the free lig-
and (CQDP) was observed for NH and H1’ in the 1H
NMR spectra and C4 in the 31C NMR spectra (Table 1).
All other chloroquine protons and carbons showed smaller
displacements, indicating that CQDP is bound to the palla-
dium through the NH atom of the secondary amine, a
good donor site in this molecule. Additionally, one signal
was observed in the 31P-NMR corresponding to the
H2PO4
− group of CQDP (see Additional file 1). Based on
the experimental data available, the formulation for the
new palladium-chloroquine diphosphate compounds cor-
responds to 16-electron Pd(II) complexes in the usual d8
square planar coordination geometry, of trans configur-
ation due to steric repulsion between the two chloroquine
diphosphate ligands.
Since the biological test are carried out using DMSO
solution, it is important to mention that the metal com-
plexes reported here are stable in this solvent, theirFigure 1 Structure of metal-chloroquine and metal chloroquine diphoNMR spectra in DMSO-d6 remain unchanged for several
days at room temperature, showing no evidence of dis-
placement of the CQ ligand by the solvent or any de-
composition of these complexes. Worthy of mentioning
is that only AuClCQ showed color change after 12 hours,
however the 1HNMR spectrum showed the characteris-
tic peaks for CQ ligand coordinated to the gold.
Anti-malarial activity
In vitro anti-malarial activity studies were carried out in
Plasmodium falciparum parasite, using a chloroquine-
susceptible (CQS) strain (3D7) and chloroquine-resistant
(CQR) strain (W2); the results are given in Table 2. The
anti-malarial drug CQDP was used as a reference. All
tested metal-CQ and metal-CQDP complexes displayed
very high anti-malarial activity against the CQS strain
(3D7), in general all metal complexes showed better ac-
tivity than CQDP, except Pd(CQDP)2I2 which showed
the less activity (IC50 = 24 nM). Suggesting that, metals
like gold and platinum achieved to improve the antiplas-
modial activity of CQDP. However, this trend was not
observed when the studied metal complexes were tested
against the CQR strain (W2), the result revealed that Pt
(CQDP)2Cl2 was the most active compound (IC50 = 89
nM) of these series, followed by Au(CQ)(TaTg) and Pt
(CQDP)2I2 which displayed similar antiplasmodial activ-
ity IC50 = 175 nM and IC50 = 177 nM respectively; thesesphate evaluated.
Table 1 Displacement of protons and carbons (Δδ, ppm)
of the CQDP in complex 6 with respect to the free
ligands (DMSO as solvent)
Protons δ (ppm) Δδ (ppm) Carbons δ (ppm) Δδ (ppm)
H6' 1.16 0.16 C9 155.38 3.26
H1'' 1.31 0.06 C2 143.62 2.35
H2' and H3' 1.72 0.09 C4 138.99 9.72
H4' and H5' 3.10 0.03 C7 138.66 3.08
H1' 4.16 0.31 C6 127.29 2.71
H3 6.99 0.13 C5 126.25 1.06
H6 7.82 0.21 C8 119.59 0.28
H8 7.91 0.11 C10 115.85 2.00
H2 8.58 0.04 C3 99.31 0.02
H5 8.64 0.15 C4' 51.09 0.32
NH 8.86 1.80 C1' 49.67 1.55
NH+ 13.65 - C2' 32.44 0.68
C3' 20.62 0.83
C1'' 20.00 0.26
C6’ 9.11 0.51
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(IC50 = 406 nM), the rest of the studied metal complexes
were less active than CQDP, although not clear trend
was observed, it is noticeable that Pt(CQDP)2Cl2 was the
most active complex against CQS and CQR. The IC50
values found in the 3D7 CQS strain are equivalent to
those found in CQS laboratory strains or field isolates for
the ferroquine, the 7-chloro-4-[(2-N,N-dimethylamino-
methyl)ferrocenyl-methylamino]quinoline, ruthenoquine or
2-phenylindoles and 3-ferrocenylmethyl-2-phenylindoles
but those obtained in the W2 CQR strain are higher than
those found in CQR laboratory strains or field isolates for
the two metalloquines [28-32]. However, the in vitro activ-
ity of these different compounds exhibited higher activityTable 2 In vitro antimalarial activity and interaction with hem
Compound Interaction with hemin Inhibition of β-hema
3D7(nM)a W2(nM)a Log K
(1) Au(CQ)(Cl) 10 (1.80) 483 (0.84) 4.76 ±
(2) Au(CQ)(TaTg) 15 (1.20) 175 (2.32) 4.63 ±
(3) Pt(CQDP)2(Cl)2 7 (2.57) 89 (4.56) 4.89 ±
(4) Pt(CQDP)2(I)2 10 (1.80) 177 (2.29) 4.85 ±
(5) Pd(CQ)2(Cl)2 12 (1.50) 653 (0.62) 4.09 ±
(6) Pd(CQDP)2(I)2 24 (0.75) 608 (0.67) 4.45 ±
CQDP 18 (−−) 406 (−−) 5.01 ±
HAI50 is the drug-to-hemin ratio required to inhibit 50% of heme aggregation again
aValues in parentheses are the relative activity with respect to CQDP. The IC50 value
dpH ~ 5.
eAfter 24 h reaction.
fAfter 2 h reaction.than those in the micromolar range obtained with pyra-
zole palladium or platinum complexes [33], rhenium-4-
aminoquinolines [34], ferrocene-ciprofloxacin complexes
[35,36] and ferrocenyl-chalcones [37]. All tested metal
complexes are more active against CQS than CQR. These
data suggest that the activity of present compounds is cor-
related with that of CQ. Previous studies suggested that
metal coordination to CQ reduces or abolished cross-
resistance [28,31]. The ferroquine and ruthenoquine
were correlated to each other but not with CQ, con-
firming the lack of cross-resistance. However, in some
works, some rhenium bioorganometallics based on the
4-aminoquinoline structure were less active in vitro
against the W2 CQR strain than the 3D7 CQS [34]. A lar-
ger number of strains with several susceptibility profiles
should be necessary to properly assess the cross-resistance
between the present compounds and CQ and conclude.
Interaction with haemin and inhibition of β-haematin
formation
Chloroquine and its metal derivatives have shown that
they can act through the formation of adducts with ferri-
protoporphyrin IX, thus blocking haemozoin formation
[15,16,38]. Indeed, in previous studies we have indicated
that the anti-malarial activity of metal-CQ complexes
often correlated with the interaction with haemin and β –
haematin inhibition (10,13,14]. Following similar studies
to those published previously, the association constant of
complexes 1–6 with ferriprotoporphyrin IX (Fe(III)PPIX)
were determined (Table 2). This association was followed
by spectrophotometric titration at the 402 nm Soret band
in aqueous DMSO at pH 5, to the equation for a 1:1 com-
plexation model using nonlinear least squares fitting,
strictly following the procedure of Egan et al. [21]. As an
example, in Figure 2 is shown the needed concentration of
complex 6 to reach the saturation point, and the hypo-
chromism was approximately 70%. The log K value ofin, inhibition of β-hematin formation
tin formation
d IR HAI50 (mM) in buffer
e HAI50 (mM) in interface
f
0.20 + 0.82 ± 0.04 (0.2) 0.99 ± 0.08 (2.3)
0.03 + 0.75 ± 0.05 (0.2) 2.32 ± 0.11 (0.9)
0.10 + 1.88 ± 0.11 (0.1) 2.09 ± 0.61 (1.1)
0.09 + 0.52 ± 0.06 (0.3) 1.86 ± 0.06 (1.2)
0.04 + 0.46 ± 0.02 (0.3) 1.88 ± 0.81 (1.2)
0.02 + 0.34 ± 0.08 (0.4) 2.21 ± 0.12 (1.0)
0.01 + 0.15 ± 0.03 (1) 2.23 ± 0.09 (1.0)
st a control experiment in the absence of drugs.
s are the mean of 6 experiments.
Figure 2 Variation in absorbance of Fe(III)PPIX at 402 nm as a function of complex 6 concentration. Conditions: 40% DMSO, apparent
pH 7.5, 0.020 M HEPES buffer, [Complex 6] = 26.98x10−6 M 25°C. Insert: log [(A-Ao) (A∞-A)] vs log [complex 6] (M).
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mental conditions (pH 7.5) is in excellent agreement with
the value reports for this method [21], in the case of log
K for the studied complexes (1–6) was obtained fitted
in a strictly analogous manner, the range of log K values
are between 4.05 and 4.87 (Table 2), this indicates that
complexes 1–6 interact with haematin comparably that
CQDP does, under used conditions. Additionally, it is
important of mentioning that these values are in the
range of ferroquine, which has demonstrated high anti-
malarial activity [5].
A first approximation to study the inhibition of β-
haematin formation was done qualitatively using FTIR
spectroscopy, monitoring the absence of characteristic
β-haematin bands at 1660 and 1210 cm−1 [22] which are
obtained in the control experiment in the absence of CQ
and studied metal complexes. However, the IR spectra
obtained when the same experiment was done in the
presence of 3 equivalents of CQ and each studied metal
complexes (separate experiments) showed the absence of
the bands at 1660 and 1210 cm−1 making evident that β-
haematin was not produced, similarly to previous obser-
vations for CQ, other organic antiplasmodial compounds
[22] and metal-CQ complexes [5].
The interesting results previously discussed motivated
the study of the effect of complexes 1–6 on the haem
aggregation inhibition activity assays (HAIA), which
was determined using two set of experiments, the firstone was carried out in buffer while a second set was
performed in an interface n-octanol/ aqueous buffer
interface; these results were compared to those ones
obtained for CQDP as control (Table 2).
The IC50 values measured for these complexes in
acetate buffer at pH 5 shown that complexes 1–6 in-
hibit the haem aggregation process at higher IC50 than
the one obtained for CQDP. Similar results were ob-
tained by this method for [RuCl2(CQ)]2 [13] and [Au
(CQ)(PPh3)]PF6 [14] complexes previously published,
where no correlation was observed between the inhib-
ition of the haem aggregation in buffer with their anti-
malarial activities against CQR strains. Therefore, a
more realistic condition in the interfaces where the β-
haematin assembles rapidly and spontaneously occurred
was used following an adaptation of the procedure de-
scribed by Egan et al. [24] and reported by Sánchez-Del-
gado et al. [25], in which the haematin is carefully
introduced close to the interface after the drug has been
equilibrated between the two phases, the overall aggrega-
tion process is much faster (60 min) through this method.
The activity trend changes drastically with respect to the
results of the assay in aqueous buffer. The complexes 1–6
was comparable or 2.3 times better inhibitor than CQDP
on the inhibition of the haem aggregation near the inter-
face, providing a plausible explanation for the enhanced
anti-plasmodial activity displayed for these studied metal
complexes.
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The synthesis and characterization of a new Pd-CQDP
(6) complex was achieved and together with complexes
1–5 were tested against two strain of malarial parasite,
finding that all these complexes displayed very high anti-
malarial activity against the CQS strain (3D7), while only
complexes 2, 3 and 4 were up to four times more active
than CQDP against CQR strain (W2). Complexes 1–6
interact with haem and inhibit β-haematin formation to
a greater extent than chloroquine diphosphate (CQDP)
and other known metal-based anti-malarial agents. Put-
ting together all of these results, it is possible to suggest
that the enhanced of the antiplasmodial activity dis-
played for these studied metal complexes is related to
their ability to inhibit β-haematin formation.
Additional file
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